Protocol of a randomized controlled trial testing inhaled Nitric Oxide in mechanically ventilated patients with severe acute respiratory syndrome in COVID-19 (SARS-CoV-2)

Chong Lei, Binxiao Su, Hailong Dong, Andrea Bellavia, Raffaele Di Fenza, Bijan Safaee Fakhr, Stefano Gianni, Luigi Giuseppe Grassi, Robert Kacmarek, Caio Cesar Araujo Morais, Riccardo Pinciroli, Emanuele Vassena, Lorenzo Berra, Chong Lei, Binxiao Su, Hailong Dong, Andrea Bellavia, Raffaele Di Fenza, Bijan Safaee Fakhr, Stefano Gianni, Luigi Giuseppe Grassi, Robert Kacmarek, Caio Cesar Araujo Morais, Riccardo Pinciroli, Emanuele Vassena, Lorenzo Berra

Abstract

Introduction: Severe acute respiratory syndrome due to novel Coronavirus (SARS-CoV-2) related infection (COVID-19) is characterized by severe ventilation perfusion mismatch leading to refractory hypoxemia. To date, there is no specific treatment available for 2019-nCoV. Nitric oxide is a selective pulmonary vasodilator gas used as a rescue therapy in refractory hypoxemia due to acute respiratory distress syndrome (ARDS). In has also shown in-vitro and clinical evidence that inhaled nitric oxide gas (iNO) has antiviral activity against other strains of coronavirus. The primary aim of this study is to determine whether inhaled NO improves oxygenation in patients with hypoxic COVID-19. This is a multicenter randomized controlled trial with 1:1 individual allocation. Patients will be blinded to the treatment. Methods and analysis. Intubated patients admitted to the intensive care unit with confirmed SARS-CoV-2 infection and severe hypoxemia will be randomized to receive inhalation of NO (treatment group) or not (control group). Treatment will be stopped when patients are free from hypoxemia for more than 24 hours. The primary outcome evaluates levels of oxygenation between the two groups at 48 hours. Secondary outcomes include rate of survival rate at 28 and 90 days in the two groups, time to resolution of severe hypoxemia, time to achieve negativity of SARS-CoV-2 RT-PCR tests. Ethics and dissemination. The study protocol has been approved by the Investigational Review Board of Xijing Hospital (Xian, China) and by the Partners Human Research Committee (Boston, USA). Recruitment will start after approval of both IRBs and local IRBs at other enrolling centers. Results of this study will be published in scientific journals, presented at scientific meetings, reported through flyers and posters, and published on related website or media in combating against this widespread contagious diseases.

Trial registration: Clinicaltrials.gov. NCT04306393.

Conflict of interest statement

Competing interests statement

LB salaries are partially supported by NIH/NHLBI 1 K23 HL128882–01A1.

Figures

Flowchart
Flowchart

References

    1. Huang C., et al., Clinical features ofpatients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 2020. 395(10223): p. 497–506.
    1. Zhu N., et al., A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med, 2020. 382(8): p. 727–733.
    1. WHO, .
    1. WHO, Coronavirus disease 2019 (COVID-19) Situation Report - 37. 2020.
    1. Wang D., et al., Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA, 2020.
    1. Yang X., et al., Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine, 2020.
    1. Xu Z., et al., Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine, 2020.
    1. Gebistorf F., et al., Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. Cochrane Database Syst Rev, 2016(6): p. CD002787.
    1. Chen L., et al., Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome: a rescue trial in Beijing. Clin Infect Dis, 2004. 39(10): p. 1531–5.
    1. Keyaerts E., et al., Inhibition of SARS-coronavirus infection in vitro by S-nitroso-Nacetylpenicillamine, a nitric oxide donor compound. Int J Infect Dis, 2004. 8(4): p. 223–6.
    1. Wright R.O., Lewander W.J., and Woolf A.D., Methemoglobinemia: Etiology, Pharmacology, and Clinical Management. Annals of Emergency Medicine, 1999. 34(5): p. 646–656.
    1. Feiner J.R. and Bickler P.E., Improved Accuracy of Methemoglobin Detection by Pulse CO-Oximetry During Hypoxia. Anesthesia & Analgesia, 2010. 111(5): p. 1160–1167.
    1. Lien T.-C., et al., Characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients. Journal of Critical Care, 2008. 23(4): p. 557–564.
    1. Talmor D., et al., Mechanical Ventilation Guided by Esophageal Pressure in Acute Lung Injury. New England Journal of Medicine, 2008. 359(20): p. 2095–2104.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit